Virtus LifeSci Biotech Clinical Trials ETF (BBC)
Summary
BBC Chart
Biotech ETF (BBC) Touches Fresh 52-Week High
Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.
Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Significant Increase in Short Interest
Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 40,613 shares, a growth of 122.6% from the February 12th total of 18,241 shares. Based on an average daily trading
Biotech ETF (BBC) Hits New 52-Week High
Biotech ETF BBC hits a 52-week high amid renewed sector momentum, Fed rate cuts and AI-driven healthcare gains, hinting at more near-term upside.
Virtus LifeSci Biotech Clinical Trials ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 110 | $5,651.09 | $4,662.9 | -$988.19 | -17.49% |
| BB Bryan Buchert Kera Capital Partners Inc. | 84,970 | $3.47M | $3.6M | $131,533.3 | 3.79% |
Virtus LifeSci Biotech Clinical Trials ETF (BBC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Virtus LifeSci Biotech Clinical Trials ETF ever had a stock split?
Virtus LifeSci Biotech Clinical Trials ETF Profile
| ARCA Exchange | US Country |
Overview
This company is a specialized investment fund that focuses its investment strategy primarily on the biotechnology sector. Under normal market conditions, it commits at least 80% of its assets towards securities that are part of a specified index. This index is designed to reflect the performance of U.S. exchange-listed biotechnology companies. Specifically, it targets companies that are in the critical stages of clinical trials (Phase 1, Phase 2, or Phase 3) for their lead drug products, which have not yet received marketing approval. The investment fund's strategy is to capitalize on the growth potential of these companies before their products reach the market, aiming to offer investors exposure to the innovative and high-potential section of the biotech industry.
Products and Services
- Component Securities Investment
The fund invests in component securities of a selected index that tracks the performance of U.S. biotechnology companies in the clinical trial stages. This product is designed for investors aiming to leverage the growth prospects of biotech companies that are on the verge of potential breakthroughs with their lead drugs, before those drugs receive marketing approval.
